158
Participants
Start Date
July 31, 2012
Primary Completion Date
July 31, 2014
Study Completion Date
November 30, 2014
recombinant human thrombopoietin (rhTPO); dexamethasone
Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
Dexamethasone
Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
Qilu Hospital, Shandong University, Jinan
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
OTHER
Anhui Medical University
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Shenzhen Second People's Hospital
OTHER
China Medical University, China
OTHER
Zhejiang Provincial Hospital of TCM
OTHER
Shandong University
OTHER